Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on nonbiologic systemic th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiu, Z.Z.N., Ashcroft, D.M., Evans, I., McElhone, K., Lunt, M., Smith, C.H., Walton, S., Murphy, R., Reynolds, N.J., Ormerod, A.D., Griffiths, C.E.M., Warren, R.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379582/
https://www.ncbi.nlm.nih.gov/pubmed/30070708
http://dx.doi.org/10.1111/bjd.17036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379582/
https://www.ncbi.nlm.nih.gov/pubmed/30070708
http://dx.doi.org/10.1111/bjd.17036

Ejemplares similares